Drug name - Mydayis

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6913768 TAKEDA PHARMS USA Sustained release delivery of amphetamine salts May, 2023

(7 months from now)

US9173857 TAKEDA PHARMS USA Controlled dose drug delivery system May, 2026

(3 years from now)

US8846100 TAKEDA PHARMS USA Controlled dose drug delivery system Aug, 2029

(6 years from now)

Drugs and Companies using AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE ingredient

Treatment: Treatment of attention deficit hyperactivity disorder

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
3.125MG;3.125MG;3.125MG;3.125MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
6.25MG;6.25MG;6.25MG;6.25MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
9.375MG;9.375MG;9.375MG;9.375MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
12.5MG;12.5MG;12.5MG;12.5MG CAPSULE, EXTENDED RELEASE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.